Last reviewed · How we verify
NCT07374835: MLA-BMI-LLE
BMI Stratified Management Based on Meridian-Lymph Axis Theory for Lower Extremity Lymphedema After Gynecologic Cancer Surgery
NA trial testing Meridian-Lymph Axis Based BMI Stratified Management in Lower Extremity Lymphedema After Gynecologic Cancer Surgery in 60 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | Hong Zhang |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 9 October 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Meridian-Lymph Axis Based BMI Stratified Management
- Routine Lymphatic Edema Care
Conditions studied
- Lower Extremity Lymphedema After Gynecologic Cancer Surgery — all drugs for Lower Extremity Lymphedema After Gynecologic Cancer Surgery →
Sponsor
Hong Zhang — full company profile →
Who can join
Adults 18 to 75, female only, with Lower Extremity Lymphedema After Gynecologic Cancer Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the impact of a BMI-stratified intervention program based on the meridian-lymphatic axis theory on the incidence of lower extremity lymphedema in postoperative patients with gynecological malignant tumors at 1 month, 3 months, and 6 months, and to validate the precision and effectiveness of this program compared to traditional CDT. Primary objectives: to evaluate the effects of this program on reducing the incidence of lymphedema, alleviating lymphedema-related symptoms (assessed via GCLQ score), improving patients' quality of life (assessed via LLQoL score), and enhancing patients' self-management behaviors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07374835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hong Zhang trials
Trials by the same sponsor.
- NCT07069075 — Gene Polymorphisms, Skin Barrier, and Inflammation in Acne · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07374835 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hong Zhang
- Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07374835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing